UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 3,680 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC decreased its holdings in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) by 12.2% during the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 26,441 shares of the company’s stock after selling 3,680 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.05% of Spyre Therapeutics worth $778,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of SYRE. Amalgamated Bank bought a new position in Spyre Therapeutics in the 2nd quarter valued at $28,000. Quest Partners LLC purchased a new position in Spyre Therapeutics in the 2nd quarter worth about $36,000. SG Americas Securities LLC bought a new stake in Spyre Therapeutics during the 2nd quarter valued at about $130,000. Intech Investment Management LLC purchased a new stake in Spyre Therapeutics in the 3rd quarter valued at about $246,000. Finally, Carlyle Group Inc. bought a new position in Spyre Therapeutics in the 2nd quarter worth about $227,000. 80.39% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

SYRE has been the subject of several research analyst reports. Robert W. Baird lifted their price target on shares of Spyre Therapeutics from $50.00 to $65.00 and gave the company an “outperform” rating in a research note on Wednesday, November 13th. Wedbush reaffirmed an “outperform” rating and set a $45.00 target price on shares of Spyre Therapeutics in a research report on Friday, November 8th. Finally, Guggenheim increased their price target on Spyre Therapeutics from $50.00 to $65.00 and gave the stock a “buy” rating in a research report on Friday, October 25th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat, Spyre Therapeutics currently has an average rating of “Buy” and a consensus target price of $51.50.

Spyre Therapeutics Trading Down 0.1 %

Shares of NASDAQ SYRE opened at $23.13 on Friday. Spyre Therapeutics, Inc. has a 12-month low of $15.41 and a 12-month high of $47.97. The stock’s fifty day simple moving average is $30.35 and its two-hundred day simple moving average is $28.96. The stock has a market capitalization of $1.19 billion, a PE ratio of -3.10 and a beta of 2.82.

Spyre Therapeutics Profile

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).